v3.26.1
Revenue
 6 Months Ended
Jul. 03, 2026
Revenue [Abstract]  
Revenue Revenue
The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company’s revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic/product type groups within its segments:

Three Months EndedSix Months Ended
July 3, 2026July 4, 2025July 3, 2026July 4, 2025
(In thousands)
Prevention & Recovery:
U.S. Bracing & Support$127,610 $120,850 $242,493 $235,936 
U.S. Other P&R (1)
59,637 70,823 115,499 137,445 
International P&R101,001 98,897 202,274 189,773 
Total Prevention & Recovery288,248 290,570 560,266 563,154 
Reconstructive:
U.S. Recon137,829 129,493 287,037 267,370 
International Recon156,705 144,482 324,630 292,855 
Total Reconstructive 294,534 273,975 611,667 560,225 
Total$582,782 $564,545 $1,171,933 $1,123,379 
(1) The three and six months ended July 4, 2025 include $14.4 million and $27.2 million, respectively, of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line.

Given the nature of its businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year.

The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue.

Allowance for Credit Losses

The Company’s estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model considers current conditions and reasonable and supportable forecasts for current and projected macroeconomic factors.

A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
Six Months Ended July 3, 2026
Balance at
Beginning
of Period		Charged to Expense, netWrite-Offs, Deductions, and Other, netForeign
Currency
Translation		Balance at
End of
Period
(In thousands)
Allowance for Credit Losses$25,609 $5,477 $(2,633)$(269)$28,184